EichorEICHOR
Condition: Pcsk9 Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Pcsk9

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Phase 3 · 18 location(s) · Hasten Biopharmaceutical Co., Ltd. · NCT06568471Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography
Phase 4 · 1 location(s) · First Affiliated Hospital of Xinjiang Medical University · NCT06520904A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis
Phase N/A · 1 location(s) · Changhai Hospital · NCT07036991Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
NA · 2 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT05397405Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Phase 4 · 1 location(s) · University Medical Centre Ljubljana · NCT07581808A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
Phase 1 · 2 location(s) · Monash University · NCT07428473Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT An
NA · 6 location(s) · Second Affiliated Hospital, Zhejiang University, School of M · NCT06863545Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Phase 1 · 1 location(s) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NCT04781322Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy f
Phase 3 · 1 location(s) · Shanghai East Hospital · NCT07002476PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Phase 4 · 19 location(s) · Peking Union Medical College Hospital · NCT06902740A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and
Phase 2 · 29 location(s) · Novartis Pharmaceuticals · NCT07610278Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
Phase 2 · 1 location(s) · Daping Hospital and the Research Institute of Surgery of the · NCT07468630Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
Phase 4 · 5 location(s) · Shanghai Tong Ren Hospital · NCT05292404A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibi
Phase 2/Phase 3 · 1 location(s) · Beijing Suncadia Pharmaceuticals Co., Ltd · NCT07404553Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Phase 4 · 2 location(s) · Shanghai Tong Ren Hospital · NCT04731155Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke
Phase N/A · 1 location(s) · First Affiliated Hospital of Harbin Medical University · NCT07540741A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Phase N/A · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT05994274Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids
NA · 1 location(s) · Institut de Recherches Cliniques de Montreal · NCT04485871Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Perc
Phase 4 · 125 location(s) · Duke University · NCT06909565Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of
Phase N/A · 1 location(s) · Yun Dai Chen · NCT06738758Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2 · 5 location(s) · Second Affiliated Hospital, Zhejiang University, School of M · NCT07061535LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
NA · 1 location(s) · China National Center for Cardiovascular Diseases · NCT05765370The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk
Phase 4 · 1 location(s) · Brigham and Women's Hospital · NCT05152888Very Early PCSK9 Inhibition for Acute Myocardial Infarction
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT07208006A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familia
Phase 2/Phase 3 · 38 location(s) · Merck Sharp & Dohme LLC · NCT07058077Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis
Phase 3 · 1 location(s) · Beijing Anzhen Hospital · NCT04968509Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Phase N/A · 27 location(s) · Federico II University · NCT05430828
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.